These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38042464)

  • 21. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development.
    Dave BP; Shah YB; Maheshwari KG; Mansuri KA; Prajapati BS; Postwala HI; Chorawala MR
    Cell Mol Neurobiol; 2023 Nov; 43(8):3847-3884. PubMed ID: 37725199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trials of new drugs for Alzheimer disease.
    Huang LK; Chao SP; Hu CJ
    J Biomed Sci; 2020 Jan; 27(1):18. PubMed ID: 31906949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's disease: emerging trends in small molecule therapies.
    Mohamed T; Rao PP
    Curr Med Chem; 2011; 18(28):4299-320. PubMed ID: 21861820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules.
    Umar T; Hoda N
    Curr Top Med Chem; 2017; 17(31):3370-3389. PubMed ID: 29332579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Strategies and Novel Drug Approaches for Alzheimer Disease.
    Ghai R; Nagarajan K; Arora M; Grover P; Ali N; Kapoor G
    CNS Neurol Disord Drug Targets; 2020; 19(9):676-690. PubMed ID: 32679025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanistic Insight into the Design of Chemical Tools to Control Multiple Pathogenic Features in Alzheimer's Disease.
    Han J; Du Z; Lim MH
    Acc Chem Res; 2021 Oct; 54(20):3930-3940. PubMed ID: 34606227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategies for Alzheimer's disease in clinical trials.
    Godyń J; Jończyk J; Panek D; Malawska B
    Pharmacol Rep; 2016 Feb; 68(1):127-38. PubMed ID: 26721364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination Therapy for the Treatment of Alzheimer's Disease: Recent Progress and Future Prospects.
    Shirbhate E; Patel VK; Tiwari P; Kore R; Veerasamy R; Mishra A; Rajak H
    Curr Top Med Chem; 2022; 22(22):1849-1867. PubMed ID: 36082857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach.
    Dorababu A
    Bioorg Chem; 2019 Dec; 93():103299. PubMed ID: 31586701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Br J Pharmacol; 2016 Jul; 173(13):2080-94. PubMed ID: 26332830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.
    Chen Y; Fu AKY; Ip NY
    Pharmacol Ther; 2019 Mar; 195():186-198. PubMed ID: 30439458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development.
    Cutler NR; Sramek JJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Jan; 25(1):27-57. PubMed ID: 11263756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of Successful Symptomatic Treatment in Parkinson's Disease for Therapeutic Strategies of Alzheimer's Disease.
    Zhao L; Cheng X; Zhong C
    ACS Chem Neurosci; 2019 Feb; 10(2):922-930. PubMed ID: 30474958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron.
    Saeedi M; Rashidy-Pour A
    Biomed Pharmacother; 2021 Jan; 133():110995. PubMed ID: 33232931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Berberine derivatives as inhibitors of acetylcholinesterase: A systematic review.
    Singh YP; Kumar H
    Chem Biol Drug Des; 2023 Dec; 102(6):1592-1603. PubMed ID: 37665093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
    Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.